Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Using circulating tumour DNA studies to improve the management of prostate cancer patients

Date

10 Oct 2016

Session

Biomarker strategies to improve the treatment of castration-resistant prostate cancer

Presenters

Gerhardt Attard

Authors

G. Attard

Author affiliations

  • The Institute for Cancer Research, SH2 5NG - Sutton/GB
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Resources from the same session

What is the role of CTCs?

Presenter: Howard Scher

Session: Biomarker strategies to improve the treatment of castration-resistant prostate cancer

Resources:

Presentation

Webcast

Introduction

Presenter: David Olmos

Session: Biomarker strategies to improve the treatment of castration-resistant prostate cancer

Resources:

Webcast

Conclusions and clinical perspectives

Presenter: Felix Feng

Session: Biomarker strategies to improve the treatment of castration-resistant prostate cancer

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings